Contact Us

Mirapex
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Did you experience compulsive gambling while taking this drug?

Estimated amount of money lost due to compulsive gambling:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Mirapex, Other Parkinson's Disease Drugs Linked Compulsive Gambling, Hypersexuality

Apr 14, 2009 | Parker Waichman LLP

connected  According to researchers at the Mayo Clinic, one in five patients  taking such drugs in a recent study developed behavior disorders, such as compulsive gambling or hypersexuality.

Dopamine agonists like Mirapex have long been suspected of causing compulsive behavior.  The suspicion was bolstered last June, when researchers investigating the link between dopamine agonists and compulsive behavior presented their findings at  International Congress of Parkinson’s Disease and Movement Disorders conference in Chicago.  The study, which looked at more than 3,000 patients from 46 medical centers in the United States and Canada, found that Parkinson’s patients on dopamine agonists are nearly three times more likely to have at least one impulse-control disorder - including gambling addiction - compared with patients receiving other treatments.

Parkinson's Disease occurs because of a lack of  the neurotransmitter dopamine in certain areas of the brain.  A dopamine agonist works by mimicking the effects of this chemical.    However, dopamine is also known to produce a “rush” in the brain of people who are anticipating a reward or excitement.  Many experts believe that such a biochemical reaction is behind the reports of compulsive behavior linked to dopamine agonists like Mirapex. 

The Mayo Clinic study involved 267 patients treated between 2004 and 2006 in a seven-county area around the Mayo clinic. Sixty-six were taking a dopamine agonist at a therapeutic level, but only 38 were using doses in the therapeutic range, 178 were taking carbidopa/levodopa without a dopamine agonist, and 23 were untreated.

Six of the patients taking dopamine agonists developed a behavioral disorder (an  occurrence rate of 18.4 percent for this group).  Five developed a  gambling addiction and five became hypersexual (both disorders developed in three of the patients). Other compulsive behaviors were noted as well.  Though in some cases the behaviors continued for years, the Mayo Clinic researchers found that they abated when the patients stopped dopamine agonist therapy.

None of these behaviors were  seen in untreated patients, those taking less than a therapeutic dose of a dopamine agonist, or patients receiving treatment with carbidopa/levodopa alone, the researchers said.

The researchers advised that the severity of the problems seen indicated that patients and doctors needed to be more aware of the behavioral side effects associated with dopamine agonists.  In at least 2 cases, patients were subjected to intense psychiatric treatment before dopamine agonists were recognized as a likely cause of their disorder.

"Physicians treating Parkinson's Disease with dopamine agonists should obviously warn the patients, spouses, and families of such risks because they may not recognize the relationship to the drug until disastrous consequences have occurred," the study authors said.


Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo